高リン血症治療の世界市場規模調査＆予測、薬剤クラス別、流通チャネル別、地域別分析、2023～2030年

高リン血症治療の世界市場は、2022年に約12億3,000万米ドルと評価され、予測期間2023～2030年には8.2％以上の健全な成長率で成長すると予測されています。

高リン血症治療は、慢性腎臓病（CKD）やその他の腎障害に関連することが多い、血中リン酸濃度の上昇を管理することを目的としています。治療法には通常、リン酸塩の摂取を制限するための食事療法、消化管での吸収を抑えるためのリン酸塩結合剤、腎臓からのリン酸塩排泄を促進する薬剤療法が含まれます。カルシウム系または非カルシウム系薬剤などのリン酸塩結合剤は、消化管内で食餌性リン酸塩と結合し、血流への吸収を阻止することにより、リン酸塩濃度を低下させるのに役立ちます。さらに、腸でのリン酸塩の吸収を抑えるためにテナパノールなどの薬剤が使用されることもあります。CKDが進行した段階では、血液中の過剰なリン酸塩を除去するために透析が行われることが多いです。治療法の選択は、高リン血症の重症度、基礎となる腎機能、個々の患者の因子によって異なります。心血管疾患、骨障害、軟部組織石灰化などの合併症を予防するためには、リン酸値のモニタリングと管理が極めて重要です。高リン血症治療市場が拡大している背景には、一般市民の意識の高まりや診断能力の向上、腎透析の増加、高齢化人口の増加、薬剤治療法の進歩などの要因があります。

加えて、慢性腎臓病（CKD）の有病率の上昇が、効率的な高リン血症治療の必要性を促進しており、これが世界全体の市場成長の触媒として作用しています。例えば、2023年に米国疾病予防管理センター（CDC）は、米国人口の14％を占める3,550万人がCKDに罹患していると報告しました。高リン血症はCKDと透析患者の間で広くみられます。したがって、これらの疾患の負担の増加は、高リン血症発生の増加と相関しています。したがって、これらの前述の要因は、推定期間中の高リン血症治療市場の成長を推進しています。さらに、革新的な高リン血症治療オプションの開発の高まりや、ますます実施される償還政策は、予測期間中に様々な有利な機会を提示します。しかし、高リン血症治療の使用による合併症や医療アドヒアランスの悪さが、2023～2030年の予測期間を通じて市場成長に課題を投げかけています。

高リン血症治療の世界市場調査において考慮した主要地域には、アジア太平洋、北米、欧州、ラテンアメリカ、中東・アフリカが含まれます。北米は、透析を受けるCKD患者の人口増加により、2022年の市場を独占しました。米国国立糖尿病消化器腎臓病研究所（NIDDK）が2023年5月に発表したデータによると、米国では約80万8,000人が末期腎不全（ESRD）に罹患しており、そのうち69％が透析を受けています。この人口動向は、予測期間を通じて高リン血症治療の需要を著しく促進すると予想されます。一方、アジア太平洋は予測期間中最も高いCAGRで成長すると予想されています。先進国に比べてカルシウムベースのリン酸結合剤が広く使用されていることが、この地域の市場需要を大きく促進しています。また、これらの地域における処方動向の進化や透析を受ける人口の増加が、予測期間におけるアジア太平洋の高リン血症治療の需要拡大に大きく寄与しています。

本調査の目的は、近年のさまざまなセグメントと国の市場規模を明らかにし、今後数年間の市場規模を予測することです。本レポートは、調査対象国における産業の質的・量的側面の両方を盛り込むよう設計されています。

また、市場の将来的な成長を規定する促進要因や課題などの重要な側面に関する詳細情報も提供しています。さらに、主要企業の競合情勢や製品提供の詳細な分析とともに、利害関係者が投資するためのミクロ市場における潜在的な機会も組み込んでいます。

目次

第1章 エグゼクティブサマリー

第2章 世界の高リン血症治療市場の定義と範囲

• 調査目的
• 市場の定義と範囲
  • 産業の進化
  • 調査範囲
• 調査対象年
• 通貨換算レート

第3章 高リン血症治療の世界市場力学

• 高リン血症治療市場の影響分析（2020～2030年）
  • 市場促進要因
    • 社会的認知の高まりと診断能力の向上
    • 慢性腎臓病（CKD）の有病率の上昇
  • 市場の課題
    • 高リン血症治療の使用による合併症
    • 服薬アドヒアランスの低下
  • 市場機会
    • 革新的な高リン血症治療法の開発の増加
    • 増加する償還政策

第4章 世界の高リン血症治療市場産業分析

• ポーターのファイブフォースモデル
  • 供給企業の交渉力
  • 買い手の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 競争企業間の敵対関係
• ポーターのファイブフォース影響分析
• PEST分析
  • 政治
  • 低価格
  • 社会
  • 技術
  • 環境
  • 法律
• 主要投資機会
• 主要成功戦略
• COVID-19影響分析
• 破壊的動向
• 業界専門家の視点
• アナリストの結論・提言

第5章 高リン血症治療の世界市場：薬剤クラス別

• 市場スナップショット
• 高リン血症治療の世界市場：薬剤クラス別、実績・ポテンシャル分析
• 高リン血症治療の世界市場：薬剤クラス別、推定・予測、2020～2030年
• 高リン血症治療市場、サブセグメント分析
  • セベラマー
  • カルシウムベースのリン酸結合剤
  • 炭酸ランタン
  • 鉄ベースのリン酸結合剤
  • その他
  • 非リン酸塩結合剤

第6章 高リン血症治療の世界市場：流通チャネル別

• 市場スナップショット
• 高リン血症治療の世界市場：流通チャネル別、実績・ポテンシャル分析
• 高リン血症治療の世界市場：流通チャネル別、推定・予測、2020～2030年
• 高リン血症治療市場、サブセグメント分析
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第7章 高リン血症治療の世界市場：地域別分析

• 主要国
• 主要新興国
• 高リン血症治療市場、地域別市場スナップショット
• 北米
  • 米国
    • 薬剤クラス別、推定・予測、2020～2030年
    • 流通チャネル別、推定・予測、2020～2030年
  • カナダ
• 欧州の高リン血症治療市場スナップショット
  • 英国
  • ドイツ
  • フランス
  • スペイン
  • イタリア
  • その他の欧州
• アジア太平洋の高リン血症治療市場スナップショット
  • 中国
  • インド
  • 日本
  • オーストラリア
  • 韓国
  • その他のアジア太平洋
• ラテンアメリカの高リン血症治療市場スナップショット
  • ブラジル
  • メキシコ
• 中東・アフリカ
  • サウジアラビア
  • 南アフリカ
  • その他の中東・アフリカ

第8章 競合情報

• 主要企業のSWOT分析
• 主要市場戦略
• 企業プロファイル
  • Sanofi SE
    • 主要情報
    • 概要
    • 財務（データの入手可能性によります）
    • 製品概要
  • Takeda Pharmaceutical Company Limited
  • Lupin Limited
  • Astellas Pharma Inc.
  • Akebia Therapeutics, Inc.
  • CSL Limited
  • Ardelyx Inc.
  • Unicycive Inc.
  • Amag Pharmaceuticals Inc
  • Akebia Therapeutics Inc.

第9章 調査プロセス

• 調査プロセス
  • データ鉱業
  • 分析
  • 市場推定
  • 検証
  • 出版
• 調査属性
• 調査前提条件

LIST OF TABLES

• TABLE 1.Global Hyperphosphatemia Therapeutics Market, report scope
• TABLE 2.Global Hyperphosphatemia Therapeutics Market estimates & forecasts by Region 2020-2030 (USD Billion)
• TABLE 3.Global Hyperphosphatemia Therapeutics Market estimates & forecasts by Drug Class 2020-2030 (USD Billion)
• TABLE 4.Global Hyperphosphatemia Therapeutics Market estimates & forecasts by Distribution Channel 2020-2030 (USD Billion)
• TABLE 5.Global Hyperphosphatemia Therapeutics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 6.Global Hyperphosphatemia Therapeutics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 7.Global Hyperphosphatemia Therapeutics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 8.Global Hyperphosphatemia Therapeutics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 9.Global Hyperphosphatemia Therapeutics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 10.Global Hyperphosphatemia Therapeutics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 11.Global Hyperphosphatemia Therapeutics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 12.Global Hyperphosphatemia Therapeutics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 13.Global Hyperphosphatemia Therapeutics Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 14.Global Hyperphosphatemia Therapeutics Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 15.U.S. Hyperphosphatemia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 16.U.S. Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 17.U.S. Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 18.Canada Hyperphosphatemia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 19.Canada Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 20.Canada Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 21.UK Hyperphosphatemia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 22.UK Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 23.UK Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 24.Germany Hyperphosphatemia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 25.Germany Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 26.Germany Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 27.France Hyperphosphatemia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 28.France Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 29.France Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 30.Italy Hyperphosphatemia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 31.Italy Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 32.Italy Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 33.Spain Hyperphosphatemia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 34.Spain Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 35.Spain Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 36.RoE Hyperphosphatemia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 37.RoE Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 38.RoE Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 39.China Hyperphosphatemia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 40.China Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 41.China Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 42.India Hyperphosphatemia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 43.India Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 44.India Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 45.Japan Hyperphosphatemia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 46.Japan Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 47.Japan Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 48.South Korea Hyperphosphatemia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 49.South Korea Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 50.South Korea Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 51.Australia Hyperphosphatemia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 52.Australia Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 53.Australia Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 54.RoAPAC Hyperphosphatemia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 55.RoAPAC Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 56.RoAPAC Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 57.Brazil Hyperphosphatemia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 58.Brazil Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 59.Brazil Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 60.Mexico Hyperphosphatemia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 61.Mexico Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 62.Mexico Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 63.RoLA Hyperphosphatemia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 64.RoLA Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 65.RoLA Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 66.Saudi Arabia Hyperphosphatemia Therapeutics Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 67.South Africa Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 68.RoMEA Hyperphosphatemia Therapeutics Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 69.List of secondary sources, used in the study of global Hyperphosphatemia Therapeutics Market
• TABLE 70.List of primary sources, used in the study of global Hyperphosphatemia Therapeutics Market
• TABLE 71.Years considered for the study
• TABLE 72.Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

• FIG 1.Global Hyperphosphatemia Therapeutics Market, research methodology
• FIG 2.Global Hyperphosphatemia Therapeutics Market, Market estimation techniques
• FIG 3.Global Market size estimates & forecast methods
• FIG 4.Global Hyperphosphatemia Therapeutics Market, key trends 2022
• FIG 5.Global Hyperphosphatemia Therapeutics Market, growth prospects 2023-2030
• FIG 6.Global Hyperphosphatemia Therapeutics Market, porters 5 force model
• FIG 7.Global Hyperphosphatemia Therapeutics Market, pest analysis
• FIG 8.Global Hyperphosphatemia Therapeutics Market, value chain analysis
• FIG 9.Global Hyperphosphatemia Therapeutics Market by segment, 2020 & 2030 (USD Billion)
• FIG 10.Global Hyperphosphatemia Therapeutics Market by segment, 2020 & 2030 (USD Billion)
• FIG 11.Global Hyperphosphatemia Therapeutics Market by segment, 2020 & 2030 (USD Billion)
• FIG 12.Global Hyperphosphatemia Therapeutics Market by segment, 2020 & 2030 (USD Billion)
• FIG 13.Global Hyperphosphatemia Therapeutics Market by segment, 2020 & 2030 (USD Billion)
• FIG 14.Global Hyperphosphatemia Therapeutics Market, regional snapshot 2020 & 2030
• FIG 15.North America Hyperphosphatemia Therapeutics Market 2020 & 2030 (USD Billion)
• FIG 16.Europe Hyperphosphatemia Therapeutics Market 2020 & 2030 (USD Billion)
• FIG 17.Asia pacific Hyperphosphatemia Therapeutics Market 2020 & 2030 (USD Billion)
• FIG 18.Latin America Hyperphosphatemia Therapeutics Market 2020 & 2030 (USD Billion)
• FIG 19.Middle East & Africa Hyperphosphatemia Therapeutics Market 2020 & 2030 (USD Billion)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

Global Hyperphosphatemia Therapeutics Market is valued at approximately USD 1.23 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 8.2% over the forecast period 2023-2030. Hyperphosphatemia treatment aims to manage elevated levels of phosphate in the blood, a condition often associated with chronic kidney disease (CKD) and other renal disorders. Treatment modalities typically include dietary modifications to limit phosphate intake, phosphate binders to reduce absorption in the gastrointestinal tract, and medications to enhance phosphate excretion through the kidneys. Phosphate binders, such as calcium-based or non-calcium-based agents, help lower phosphate levels by binding to dietary phosphate in the gut and preventing its absorption into the bloodstream. Additionally, medications like tenapanor may be used to reduce phosphate absorption in the intestines. Dialysis is often employed in advanced CKD stages to remove excess phosphate from the blood. The choice of treatment depends on the severity of hyperphosphatemia, underlying kidney function, and individual patient factors. Phosphate monitoring and management of phosphate levels are crucial to prevent complications such as cardiovascular disease, bone disorders, and soft tissue calcifications. The Hyperphosphatemia Therapeutics Market is expanding because of factors such as the growing public awareness and improved diagnostic capabilities, growth of kidney dialysis, coupled with the increasing aging populations and advancements in drug therapeutics.

In addition, the rising prevalence of chronic kidney disease (CKD) is driving the need for efficient Hyperphosphatemia treatments, which is acting as a catalyzing factor for market growth across the globe. For instance, in 2023, the U.S. Centers for Disease Control and Prevention (CDC) reported that 35.5 million individuals, comprising 14% of the U.S. populace, were afflicted by CKD. Hyperphosphatemia is prevalent among CKD and dialysis patients. Thus, the rising burden of these conditions correlate with increased Hyperphosphatemia occurrence. Thus, these aforementioned factors are propelling the growth of the Hyperphosphatemia Therapeutics Market during the estimated period. Moreover, the rising development of innovative hyperphosphatemia treatment options, as well as the increasingly implementing reimbursement policies present various lucrative opportunities over the forecast years. However, the complications from use of hyperphosphatemia therapeutics and poor medical adherence are challenging the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Hyperphosphatemia Therapeutics Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the rising population of CKD patients undergoing dialysis. As per the data released by the National Institute of Diabetes and Digestive and Kidney Disorders (NIDDK) in May 2023, approximately 808,000 individuals in the U.S. were living with End-Stage Renal Disease (ESRD), with 69% of them undergoing dialysis. This demographic trend is expected to markedly drive the demand for hyperphosphatemia therapeutics throughout the forecast period. Whereas Asia Pacific is expected to grow at the highest CAGR over the forecast years. The prevalent usage of calcium-based phosphate binders compared to developed nations are significantly propelling the market demand across the region. Also, evolving prescription trends in these regions and a notably larger population undergoing dialysis contribute significantly to the heightened demand for hyperphosphatemia treatment across Asia Pacific in the forecast period.

Major market players included in this report are:

• Sanofi SE
• Takeda Pharmaceutical Company Limited
• Lupin Limited
• Astellas Pharma Inc.
• Akebia Therapeutics, Inc.
• CSL Limited
• Ardelyx, Inc.
• Unicycive, Inc.
• Amag Pharmaceuticals Inc
• Akebia Therapeutics Inc.

Recent Developments in the Market:

• In August 2023, Astellas Pharma Inc. and DivcoWest, a DivCore Capital Company, collaborated with the aim of launching Astellas' new life science center on Morgan Avenue in Cambridge.
• In July 2023, Ardelyx obtained approval for the use of Tenapanor as a hyperphosphatemia treatment in China. This regulatory clearance has facilitated the company's global market expansion by strengthening its presence in the international healthcare landscape.

Global Hyperphosphatemia Therapeutics Market Report Scope:

• Historical Data - 2020 - 2021
• Base Year for Estimation - 2022
• Forecast period - 2023-2030
• Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered - Drug Class, Distribution Channel, Region
• Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
• Customization Scope - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Drug Class:

• Sevelamer
• Calcium-based Phosphate Binders
• Lanthanum Carbonate
• Iron-based Phosphate Binders
• Non-Phosphate Binders
• Others

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Table of Contents

Chapter 1.Executive Summary

• 1.1.Market Snapshot
• 1.2.Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
  • 1.2.1.Hyperphosphatemia Therapeutics Market, by Region, 2020-2030 (USD Billion)
  • 1.2.2.Hyperphosphatemia Therapeutics Market, by Drug Class, 2020-2030 (USD Billion)
  • 1.2.3.Hyperphosphatemia Therapeutics Market, by Distribution Channel, 2020-2030 (USD Billion)
• 1.3.Key Trends
• 1.4.Estimation Methodology
• 1.5.Research Assumption

Chapter 2.Global Hyperphosphatemia Therapeutics Market Definition and Scope

• 2.1.Objective of the Study
• 2.2.Market Definition & Scope
  • 2.2.1.Industry Evolution
  • 2.2.2.Scope of the Study
• 2.3.Years Considered for the Study
• 2.4.Currency Conversion Rates

Chapter 3.Global Hyperphosphatemia Therapeutics Market Dynamics

• 3.1.Hyperphosphatemia Therapeutics Market Impact Analysis (2020-2030)
  • 3.1.1.Market Drivers
    • 3.1.1.1.Increasing public awareness and improved diagnostic capabilities
    • 3.1.1.2.Rising prevalence of chronic kidney disease (CKD)
  • 3.1.2.Market Challenges
    • 3.1.2.1.Complications from use of hyperphosphatemia therapeutics
    • 3.1.2.2.Poor medical adherence
  • 3.1.3.Market Opportunities
    • 3.1.3.1.Rising development of innovative hyperphosphatemia treatment options
    • 3.1.3.2.Increasingly implementing reimbursement policies

Chapter 4.Global Hyperphosphatemia Therapeutics Market Industry Analysis

• 4.1.Porter's 5 Force Model
  • 4.1.1.Bargaining Power of Suppliers
  • 4.1.2.Bargaining Power of Buyers
  • 4.1.3.Threat of New Entrants
  • 4.1.4.Threat of Substitutes
  • 4.1.5.Competitive Rivalry
• 4.2.Porter's 5 Force Impact Analysis
• 4.3.PEST Analysis
  • 4.3.1.Political
  • 4.3.2.Economical
  • 4.3.3.Social
  • 4.3.4.Technological
  • 4.3.5.Environmental
  • 4.3.6.Legal
• 4.4.Top investment opportunity
• 4.5.Top winning strategies
• 4.6.COVID-19 Impact Analysis
• 4.7.Disruptive Trends
• 4.8.Industry Expert Perspective
• 4.9.Analyst Recommendation & Conclusion

Chapter 5.Global Hyperphosphatemia Therapeutics Market, by Drug Class

• 5.1.Market Snapshot
• 5.2.Global Hyperphosphatemia Therapeutics Market by Drug Class, Performance - Potential Analysis
• 5.3.Global Hyperphosphatemia Therapeutics Market Estimates & Forecasts by Drug Class 2020-2030 (USD Billion)
• 5.4.Hyperphosphatemia Therapeutics Market, Sub Segment Analysis
  • 5.4.1.Sevelamer
  • 5.4.2.Calcium-based Phosphate Binders
  • 5.4.3.Lanthanum Carbonate
  • 5.4.4.Iron-based Phosphate Binders
  • 5.4.5.Others
  • 5.4.6.Non-Phosphate Binders

Chapter 6.Global Hyperphosphatemia Therapeutics Market, by Distribution Channel

• 6.1.Market Snapshot
• 6.2.Global Hyperphosphatemia Therapeutics Market by Distribution Channel, Performance - Potential Analysis
• 6.3.Global Hyperphosphatemia Therapeutics Market Estimates & Forecasts by Distribution Channel 2020-2030 (USD Billion)
• 6.4.Hyperphosphatemia Therapeutics Market, Sub Segment Analysis
  • 6.4.1.Hospital Pharmacies
  • 6.4.2.Retail Pharmacies
  • 6.4.3.Online Pharmacies

Chapter 7.Global Hyperphosphatemia Therapeutics Market, Regional Analysis

• 7.1.Top Leading Countries
• 7.2.Top Emerging Countries
• 7.3.Hyperphosphatemia Therapeutics Market, Regional Market Snapshot
• 7.4.North America Hyperphosphatemia Therapeutics Market
  • 7.4.1.U.S. Hyperphosphatemia Therapeutics Market
    • 7.4.1.1.Drug Class breakdown estimates & forecasts, 2020-2030
    • 7.4.1.2.Distribution Channel breakdown estimates & forecasts, 2020-2030
  • 7.4.2.Canada Hyperphosphatemia Therapeutics Market
• 7.5.Europe Hyperphosphatemia Therapeutics Market Snapshot
  • 7.5.1.U.K. Hyperphosphatemia Therapeutics Market
  • 7.5.2.Germany Hyperphosphatemia Therapeutics Market
  • 7.5.3.France Hyperphosphatemia Therapeutics Market
  • 7.5.4.Spain Hyperphosphatemia Therapeutics Market
  • 7.5.5.Italy Hyperphosphatemia Therapeutics Market
  • 7.5.6.Rest of Europe Hyperphosphatemia Therapeutics Market
• 7.6.Asia-Pacific Hyperphosphatemia Therapeutics Market Snapshot
  • 7.6.1.China Hyperphosphatemia Therapeutics Market
  • 7.6.2.India Hyperphosphatemia Therapeutics Market
  • 7.6.3.Japan Hyperphosphatemia Therapeutics Market
  • 7.6.4.Australia Hyperphosphatemia Therapeutics Market
  • 7.6.5.South Korea Hyperphosphatemia Therapeutics Market
  • 7.6.6.Rest of Asia Pacific Hyperphosphatemia Therapeutics Market
• 7.7.Latin America Hyperphosphatemia Therapeutics Market Snapshot
  • 7.7.1.Brazil Hyperphosphatemia Therapeutics Market
  • 7.7.2.Mexico Hyperphosphatemia Therapeutics Market
• 7.8.Middle East & Africa Hyperphosphatemia Therapeutics Market
  • 7.8.1.Saudi Arabia Hyperphosphatemia Therapeutics Market
  • 7.8.2.South Africa Hyperphosphatemia Therapeutics Market
  • 7.8.3.Rest of Middle East & Africa Hyperphosphatemia Therapeutics Market

Chapter 8.Competitive Intelligence

• 8.1.Key Company SWOT Analysis
• 8.2.Top Market Strategies
• 8.3.Company Profiles
  • 8.3.1. Sanofi SE
    • 8.3.1.1.Key Information
    • 8.3.1.2.Overview
    • 8.3.1.3.Financial (Subject to Data Availability)
    • 8.3.1.4.Product Summary
    • 8.3.1.5.Recent Developments
  • 8.3.2.Takeda Pharmaceutical Company Limited
  • 8.3.3.Lupin Limited
  • 8.3.4.Astellas Pharma Inc.
  • 8.3.5.Akebia Therapeutics, Inc.
  • 8.3.6.CSL Limited
  • 8.3.7.Ardelyx Inc.
  • 8.3.8.Unicycive Inc.
  • 8.3.9.Amag Pharmaceuticals Inc
  • 8.3.10.Akebia Therapeutics Inc.

Chapter 9.Research Process

• 9.1.Research Process
  • 9.1.1.Data Mining
  • 9.1.2.Analysis
  • 9.1.3.Market Estimation
  • 9.1.4.Validation
  • 9.1.5.Publishing
• 9.2.Research Attributes
• 9.3.Research Assumption